Pub Date : 2025-07-28DOI: 10.1016/j.oftal.2025.06.003
O. Teherán , C. Parra , E. Ramos , M. Ochoa , W. Escobar
Introduction
The Ahmed valve is indicated for glaucoma refractory to maximal pharmacologic therapy and properly performed filtering surgeries. Surgical success can be compromised by the formation of fibrotic tissue around the valve body; various strategies have been employed to prevent this, including the use of antimetabolites such as mitomycin C (MMC).
Aim
To evaluate the effectiveness and safety of mitomycin C (MMC) use when implanting Ahmed valve in patients with refractory glaucoma.
Methods
Cohort study involving 34 patients divided into 2 groups of 17 patients each: group 1 (MMC use) and group 2 (no MMC use), with a one-year follow-up. Complete success was defined as intraocular pressure (IOP) between 6-18 mmHg without the use of antiglaucoma medications; qualified success referred to the same IOP range but associated with antiglaucoma medications, while failure was characterized by IOP outside this range, severe complications or reintervention.
Results
The overall success rate in group 1 was 88.2%, and in group 2, 94.2%. There was an average reduction in IOP of 18.0 ± 11.5 mmHg in group 1 and 11.3 ± 5.0 mmHg in group 2 (p = 0.0352). The hypertensive phase occurred in 17.6% of the participants in the first group and the second, 70.6% (p = 0.0048).
Conclusions
The use of MMC decreases the hypertensive phase observed in Ahmed valve implant surgery, thereby achieving better IOP control.
{"title":"Evaluación de la efectividad del implante de válvula de Ahmed adicionando mitomicina C en pacientes con glaucoma refractario a un año de seguimiento","authors":"O. Teherán , C. Parra , E. Ramos , M. Ochoa , W. Escobar","doi":"10.1016/j.oftal.2025.06.003","DOIUrl":"10.1016/j.oftal.2025.06.003","url":null,"abstract":"<div><h3>Introduction</h3><div>The Ahmed valve is indicated for glaucoma refractory to maximal pharmacologic therapy and properly performed filtering surgeries. Surgical success can be compromised by the formation of fibrotic tissue around the valve body; various strategies have been employed to prevent this, including the use of antimetabolites such as mitomycin C (MMC).</div></div><div><h3>Aim</h3><div>To evaluate the effectiveness and safety of mitomycin C (MMC) use when implanting Ahmed valve in patients with refractory glaucoma.</div></div><div><h3>Methods</h3><div>Cohort study involving 34 patients divided into 2 groups of 17 patients each: group 1 (MMC use) and group 2 (no MMC use), with a one-year follow-up. Complete success was defined as intraocular pressure (IOP) between 6-18<!--> <!-->mmHg without the use of antiglaucoma medications; qualified success referred to the same IOP range but associated with antiglaucoma medications, while failure was characterized by IOP outside this range, severe complications or reintervention.</div></div><div><h3>Results</h3><div>The overall success rate in group 1 was 88.2%, and in group 2, 94.2%. There was an average reduction in IOP of 18.0<!--> <!-->±<!--> <!-->11.5<!--> <!-->mmHg in group 1 and 11.3<!--> <!-->±<!--> <!-->5.0<!--> <!-->mmHg in group 2 (p<!--> <!-->=<!--> <!-->0.0352). The hypertensive phase occurred in 17.6% of the participants in the first group and the second, 70.6% (p<!--> <!-->=<!--> <!-->0.0048).</div></div><div><h3>Conclusions</h3><div>The use of MMC decreases the hypertensive phase observed in Ahmed valve implant surgery, thereby achieving better IOP control.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 9","pages":"Pages 521-527"},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-28DOI: 10.1016/j.oftal.2025.06.006
A. Ortiz , E. García , J. Ortega , J. de Vera , E. Vázquez , M. Carrillo , V. Romero , K. Merizalde
Objective
To evaluate the measurement accuracy of 2 swept-source optical biometers, the IOLMaster 700 and the Revo FC 130, in patients diagnosed with cataracts.
Methods
We conducted a prospective, observational and comparative study in patients older than 40 years with cataracts. A single operator performed optical biometry using both devices during the same session. Cataract grading was conducted using the Lens Opacities Classification System III.
Results
Biometric measurements were obtained from the 504 eyes of 279 patients, with a mean age of 70.93 ± 8.41 years. Statistically significant differences were found between the IOLMaster 700 and Revo FC 130 in the following parameters: mean keratometry (43.53 ± 1.56 vs 44.27 ± 1.68 diopters), total average keratometry and mean keratometry (43.56 ± 1.55 diopters vs 44.27 ± 1.67 diopters), white-to-white distance (11.98 ± 0.52 vs 12.66 ± 0.73 mm), and lens thickness (4.53 ± 0.40 vs 4.60 ± 0.40 mm). No significant differences were found in axial length (23.31 ± 0.96 vs 23.25 ± 1.01 mm) or anterior chamber depth (3.02 ± 0.38 vs 3.02 ± 0.37 mm), which were not clinically relevant. No statistically significant differences were found between the IOLMaster 700 measurements of total mean keratometry (43.53 ± 1.56 diopters) and mean keratometry (43.56 ± 1.56 diopters).
Conclusions
Although most measurements do not reveal any clinically relevant differences, the 2 devices should not be used interchangeably, mainly due to variations in keratometry readings.
目的评价两种扫描源光学生物计IOLMaster 700和Revo FC 130在白内障患者中的测量精度。方法对40岁以上白内障患者进行前瞻性、观察性和比较研究。一名操作员在同一会话期间使用两种设备进行光学生物测定。采用晶状体混浊分级系统III进行白内障分级。结果279例患者504只眼获得生物特征测量，平均年龄70.93±8.41岁。IOLMaster 700与Revo FC 130在以下参数上差异有统计学意义：平均角膜屈光度（43.53±1.56 vs 44.27±1.68）、总平均角膜屈光度与平均角膜屈光度（43.56±1.55 vs 44.27±1.67）、白-白距离（11.98±0.52 vs 12.66±0.73 mm）、晶状体厚度（4.53±0.40 vs 4.60±0.40 mm）。轴长（23.31±0.96 vs 23.25±1.01 mm）和前房深度（3.02±0.38 vs 3.02±0.37 mm）差异无统计学意义，无临床意义。IOLMaster 700测量的总平均角膜屈光度（43.53±1.56屈光度）与平均角膜屈光度（43.56±1.56屈光度）无统计学差异。结论虽然大多数测量结果没有显示任何临床相关差异，但这两种设备不应交替使用，主要是由于角膜测量读数的差异。
{"title":"Comparación de dos biómetros ópticos con tecnología de fuente de barrido: IOLMaster 700 vs. Revo FC 130","authors":"A. Ortiz , E. García , J. Ortega , J. de Vera , E. Vázquez , M. Carrillo , V. Romero , K. Merizalde","doi":"10.1016/j.oftal.2025.06.006","DOIUrl":"10.1016/j.oftal.2025.06.006","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the measurement accuracy of 2 swept-source optical biometers, the IOLMaster 700 and the Revo FC 130, in patients diagnosed with cataracts.</div></div><div><h3>Methods</h3><div>We conducted a prospective, observational and comparative study in patients older than 40 years with cataracts. A single operator performed optical biometry using both devices during the same session. Cataract grading was conducted using the Lens Opacities Classification System III.</div></div><div><h3>Results</h3><div>Biometric measurements were obtained from the 504 eyes of 279 patients, with a mean age of 70.93<!--> <!-->±<!--> <!-->8.41 years. Statistically significant differences were found between the IOLMaster 700 and Revo FC 130 in the following parameters: mean keratometry (43.53<!--> <!-->±<!--> <!-->1.56 vs 44.27<!--> <!-->±<!--> <!-->1.68 diopters), total average keratometry and mean keratometry (43.56<!--> <!-->±<!--> <!-->1.55 diopters vs 44.27<!--> <!-->±<!--> <!-->1.67 diopters), white-to-white distance (11.98<!--> <!-->±<!--> <!-->0.52 vs 12.66<!--> <!-->±<!--> <!-->0.73<!--> <!-->mm), and lens thickness (4.53<!--> <!-->±<!--> <!-->0.40 vs 4.60<!--> <!-->±<!--> <!-->0.40<!--> <!-->mm). No significant differences were found in axial length (23.31<!--> <!-->±<!--> <!-->0.96 vs 23.25<!--> <!-->±<!--> <!-->1.01<!--> <!-->mm) or anterior chamber depth (3.02<!--> <!-->±<!--> <!-->0.38 vs 3.02<!--> <!-->±<!--> <!-->0.37<!--> <!-->mm), which were not clinically relevant. No statistically significant differences were found between the IOLMaster 700 measurements of total mean keratometry (43.53<!--> <!-->±<!--> <!-->1.56 diopters) and mean keratometry (43.56<!--> <!-->±<!--> <!-->1.56 diopters).</div></div><div><h3>Conclusions</h3><div>Although most measurements do not reveal any clinically relevant differences, the 2 devices should not be used interchangeably, mainly due to variations in keratometry readings.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 11","pages":"Pages 658-665"},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-26DOI: 10.1016/j.oftal.2024.09.007
M. Larrañaga Cores , M. Asencio Durán , J. Peralta Calvo , M. Feito Rodríguez , G. Amorena Santesteban , A. del Hierro Zarzuelo , A. Boto-de-los-Bueis
This is the case of a 14-years-old woman referred to our ophthalmology department with suspected iris juvenile xanthogranuloma, with reported bilateral, hematic recurrent uveitis as soon as she discontinued treatment with topical prednisolone acetate eye drops. After numerous treatments at the 3-year follow-up, including oral steroids, repeated injections of subtenon triamcinolone acetonide and intracameral and intravitreal anti-VEGF, treatment with intravitreal fluocinolone acetonide implant (ILUVIEN®) in both eyes was decided. Evolution since then and at the 10-month follow-up has been satisfactory; the patient has not exhibited any new episodes of ocular inflammation or hyphema despite the progressive withdrawal of topical corticosteroids, and vision has remained at 20/20 in both eyes. As far as we know, this is the first case of bilateral ocular juvenile xanthogranuloma successfully treated with an intravitreal fluocinolone implant.
{"title":"Implante intravítreo de acetónido de fluocinolona (ILUVIEN®) para el tratamiento del xantogranuloma ocular juvenil","authors":"M. Larrañaga Cores , M. Asencio Durán , J. Peralta Calvo , M. Feito Rodríguez , G. Amorena Santesteban , A. del Hierro Zarzuelo , A. Boto-de-los-Bueis","doi":"10.1016/j.oftal.2024.09.007","DOIUrl":"10.1016/j.oftal.2024.09.007","url":null,"abstract":"<div><div>This is the case of a 14-years-old woman referred to our ophthalmology department with suspected iris juvenile xanthogranuloma, with reported bilateral, hematic recurrent uveitis as soon as she discontinued treatment with topical prednisolone acetate eye drops. After numerous treatments at the 3-year follow-up, including oral steroids, repeated injections of subtenon triamcinolone acetonide and intracameral and intravitreal anti-VEGF, treatment with intravitreal fluocinolone acetonide implant (ILUVIEN®) in both eyes was decided. Evolution since then and at the 10-month follow-up has been satisfactory; the patient has not exhibited any new episodes of ocular inflammation or hyphema despite the progressive withdrawal of topical corticosteroids, and vision has remained at 20/20 in both eyes. As far as we know, this is the first case of bilateral ocular juvenile xanthogranuloma successfully treated with an intravitreal fluocinolone implant.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 11","pages":"Pages 710-718"},"PeriodicalIF":0.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To determine the state of ocular surface and tear film in college students who are users of inhalants, mainly vapers.
Methods
We conducted a descriptive, observational, and cross-sectional study with 62 participants whose sociodemographic characteristics, ocular surface status, tear film and variables related to vaping were evaluated. Individuals with a higher (5-7 times per week of consumption) and lower frequency of vaping (1-4 times per week of consumption) were evaluated. Symptom documentation was standardized using the OSDI questionnaire and biomicroscopy to evaluate ocular adnexa and anterior segment structures, blinking frequency and eye protection index (EPI) were also determined.
Results
A total of 76% of participants were men with a median age of 20.37 years, and an age range between 18 and 28 years. Participants with a higher frequency of vaping exhibited blepharitis (60%) (P-value >.05), meibomian gland obstruction (65.63%) (P-value >.05), tarsal conjunctival hyperemia (52.94%) (P-value < .05), tarsal conjunctival hyperemia (52.94%) (P-value < .05), generalized bulbar hyperemia (72.73%) (P-value >.05), papillary reaction (60%) (P-value >.05), conjunctival staining (75%) (P-value >.05), limbal redness (61.54%) (P-value >.05).
A normal Schirmer I (median 31 mm/5 minutes), short tear breakup time (median 3.5 seconds in BUT) and a lower number of blinks per minute (median 10.75) were found, yet the EPI was lower (median 0.58).
Conclusions
Vaping could be associated with ocular health alterations, such as blepharitis, meibomian gland obstruction, conjunctival hyperemia, conjunctival staining and altered tear quality. Follow-up studies are recommended to establish causal relationships.
{"title":"Superficie ocular y película lagrimal en estudiantes universitarios usuarios de sustancias inhalantes, principalmente vapeadores","authors":"A.B. López Álvarez, D.A. Ulloa Delgado, D.C. Palencia Flórez, M.C. Morón Barreto","doi":"10.1016/j.oftal.2025.06.007","DOIUrl":"10.1016/j.oftal.2025.06.007","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the state of ocular surface and tear film in college students who are users of inhalants, mainly vapers.</div></div><div><h3>Methods</h3><div>We conducted a descriptive, observational, and cross-sectional study with 62 participants whose sociodemographic characteristics, ocular surface status, tear film and variables related to vaping were evaluated. Individuals with a higher (5-7 times per week of consumption) and lower frequency of vaping (1-4 times per week of consumption) were evaluated. Symptom documentation was standardized using the OSDI questionnaire and biomicroscopy to evaluate ocular adnexa and anterior segment structures, blinking frequency and eye protection index (EPI) were also determined.</div></div><div><h3>Results</h3><div>A total of 76% of participants were men with a median age of 20.37 years, and an age range between 18 and 28 years. Participants with a higher frequency of vaping exhibited blepharitis (60%) <em>(P</em>-value<!--> <!-->>.05), meibomian gland obstruction (65.63%) <em>(P</em>-value<!--> <!-->>.05), tarsal conjunctival hyperemia (52.94%) <em>(P</em>-value <<!--> <!-->.05), tarsal conjunctival hyperemia (52.94%) <em>(P</em>-value <<!--> <!-->.05), generalized bulbar hyperemia (72.73%) <em>(P</em>-value<!--> <!-->>.05), papillary reaction (60%) <em>(P</em>-value<!--> <!-->>.05), conjunctival staining (75%) <em>(P</em>-value<!--> <!-->>.05), limbal redness (61.54%) <em>(P</em>-value<!--> <!-->>.05).</div><div>A normal Schirmer I (median 31<!--> <!-->mm/5<!--> <!-->minutes), short tear breakup time (median 3.5<!--> <!-->seconds in BUT) and a lower number of blinks per minute (median 10.75) were found, yet the EPI was lower (median 0.58).</div></div><div><h3>Conclusions</h3><div>Vaping could be associated with ocular health alterations, such as blepharitis, meibomian gland obstruction, conjunctival hyperemia, conjunctival staining and altered tear quality. Follow-up studies are recommended to establish causal relationships.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 11","pages":"Pages 666-673"},"PeriodicalIF":0.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-25DOI: 10.1016/j.oftal.2025.03.009
S. Amatha , R. Das , M.K. Gautam , S. Mondal
Recent years have witnessed remarkable advancements in biotechnological ocular drug delivery systems, introducing novel strategies such as gene therapy, cell-based systems, and targeted carriers. This article focuses specifically on age-related macular degeneration, the most prevalent ocular condition. While gene therapy holds promise for age-related macular degeneration treatment, it also presents significant challenges, leading to the exploration of cell-based therapy as a complementary or alternative approach. To address these hurdles and ensure successful market translation, new companies often form collaborative expert teams encompassing all relevant fields, including regulatory affairs. As medical science continues to evolve, a comprehensive understanding of gene therapy, cell-based delivery, biocompatibility, safety considerations, regulatory aspects, and ongoing clinical trials is essential to fully grasp the safety and effectiveness of these novel ocular therapies. Consequently, this paper primarily explores these key areas. The successful evolution of biotechnological ocular delivery signals a positive shift towards personalized medicine, which is expected to significantly improve the quality of life for age-related macular degeneration patients in the near future.
{"title":"Nuevos sistemas biotecnológicos de administración de fármacos para la degeneración macular asociada a la edad","authors":"S. Amatha , R. Das , M.K. Gautam , S. Mondal","doi":"10.1016/j.oftal.2025.03.009","DOIUrl":"10.1016/j.oftal.2025.03.009","url":null,"abstract":"<div><div>Recent years have witnessed remarkable advancements in biotechnological ocular drug delivery systems, introducing novel strategies such as gene therapy, cell-based systems, and targeted carriers. This article focuses specifically on age-related macular degeneration, the most prevalent ocular condition. While gene therapy holds promise for age-related macular degeneration treatment, it also presents significant challenges, leading to the exploration of cell-based therapy as a complementary or alternative approach. To address these hurdles and ensure successful market translation, new companies often form collaborative expert teams encompassing all relevant fields, including regulatory affairs. As medical science continues to evolve, a comprehensive understanding of gene therapy, cell-based delivery, biocompatibility, safety considerations, regulatory aspects, and ongoing clinical trials is essential to fully grasp the safety and effectiveness of these novel ocular therapies. Consequently, this paper primarily explores these key areas. The successful evolution of biotechnological ocular delivery signals a positive shift towards personalized medicine, which is expected to significantly improve the quality of life for age-related macular degeneration patients in the near future.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 9","pages":"Pages 537-548"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144912388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-25DOI: 10.1016/j.oftal.2025.06.001
L. López Guajardo , P. Carnota Méndez , F. González del Valle
{"title":"Éxito quirúrgico en el desprendimiento de retina regmatógeno: nuevas consideraciones en 2025","authors":"L. López Guajardo , P. Carnota Méndez , F. González del Valle","doi":"10.1016/j.oftal.2025.06.001","DOIUrl":"10.1016/j.oftal.2025.06.001","url":null,"abstract":"","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 9","pages":"Pages 511-513"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-25DOI: 10.1016/j.oftal.2025.06.010
P. Pérez-García , J.A. Gegúndez-Fernández , M. Ariño-Gutiérrez , M. Molero-Senosiaín , B. Burgos-Blasco , D. Díaz-Valle
This work aims to present a novel technique for obtaining grafts for Descemet Membrane Endothelial Keratoplasty (DMEK) safely and efficiently, thanks to its fast learning curve and reduced risk of graft tears. The technique involves the peripheral dissection of the endothelium starting with a superficial incision made using a 30-Gauge needle, 1 mm inside Schwalbe's line across 360° of the corneal periphery. Trypan Blue is then applied to visualize the dissection boundary, and a DMEK Sinskey hook is used to lift 1 mm of the peripheral graft along the entire circumference. The technique continues with the separation of Descemet's membrane from the stroma, as is commonly performed. This technique reduces costs by employing a standard needle and achieves low failure rates compared to other techniques.
{"title":"Obtención del injerto para queratoplastia endotelial de la membrana de Descemet con aguja de calibre 30 Gauge: una técnica novedosa, segura y económica","authors":"P. Pérez-García , J.A. Gegúndez-Fernández , M. Ariño-Gutiérrez , M. Molero-Senosiaín , B. Burgos-Blasco , D. Díaz-Valle","doi":"10.1016/j.oftal.2025.06.010","DOIUrl":"10.1016/j.oftal.2025.06.010","url":null,"abstract":"<div><div>This work aims to present a novel technique for obtaining grafts for Descemet Membrane Endothelial Keratoplasty (DMEK) safely and efficiently, thanks to its fast learning curve and reduced risk of graft tears. The technique involves the peripheral dissection of the endothelium starting with a superficial incision made using a 30-Gauge needle, 1<!--> <!-->mm inside Schwalbe's line across 360° of the corneal periphery. Trypan Blue is then applied to visualize the dissection boundary, and a DMEK Sinskey hook is used to lift 1<!--> <!-->mm of the peripheral graft along the entire circumference. The technique continues with the separation of Descemet's membrane from the stroma, as is commonly performed. This technique reduces costs by employing a standard needle and achieves low failure rates compared to other techniques.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 11","pages":"Pages 742-745"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-19DOI: 10.1016/j.oftal.2025.06.009
A. Lo Cascio, A. Bures Jelstrup
Thi is the case of a necrotizing retinitis associated with occlusive retinal vasculitis due to cytomegalovirus (CMV) in an immunocompetent patient with complex diagnosis and management, but with resolution after the start of appropriate antiviral therapy, with subsequent control of intraocular inflammation and visual recovery. CMV was confirmed as the pathogen using the polymerase chain reaction assay of aqueous humor samples.
{"title":"Retinitis necrosante por citomegalovirus en paciente inmunocompetente: a propósito de un caso","authors":"A. Lo Cascio, A. Bures Jelstrup","doi":"10.1016/j.oftal.2025.06.009","DOIUrl":"10.1016/j.oftal.2025.06.009","url":null,"abstract":"<div><div>Thi is the case of a necrotizing retinitis associated with occlusive retinal vasculitis due to cytomegalovirus (CMV) in an immunocompetent patient with complex diagnosis and management, but with resolution after the start of appropriate antiviral therapy, with subsequent control of intraocular inflammation and visual recovery. CMV was confirmed as the pathogen using the polymerase chain reaction assay of aqueous humor samples.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 11","pages":"Pages 719-722"},"PeriodicalIF":0.0,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-14DOI: 10.1016/j.oftal.2025.06.005
V.A. Martel Ramirez, C.R. Pérez Montaño, A.Y. Hernández Vázquez, S. Rojas Juárez, J.A. Ramírez Estudillo
Objective
This study aims to describe the phenotypic progression of patients with Stargardt disease caused by mutations in the ABCA4 gene and reports on the mutated allelic variants.
Method
We conducted an observational, ambispective, and descriptive study. Patients who had Stargardt disease by the ABCA4 gene mutation were included. The study used the genetic report and the baseline examinations appearing on health records. To evaluate the phenotypic variation, a new ophthalmological evaluation was conducted using macular OCT, retinography, autofluorescence, and electroretinogram.
Results
The study identified a total of 32 cases with a mean follow-up of 6 years. The mean age of onset was 16 years. The mean initial and final VA were 0.79 and 0.95 logMAR, respectively. The mean initial and final CMT were 142.5 and 135 microns, respectively. The predominant degree of fundus involvement and autofluorescence pattern at the beginning and end was macular atrophy with flecks and the low signal of macular autofluorescence surrounded by a heterogeneous background, respectively. Initial electroretinography showed predominantly preserved function of rods and cones, while in the end most cases presented rod and cone system dysfunction. A total of 9 cases were homozygous, and 31 different mutant allelic variants were identified. The most common variant was p.Trp1618Cys, followed by p.Ala1773Val. Two new allelic variants, p.Leu634Pro, and p.Tyr665Serfs*5, were also discovered.
Conclusions
The study found that patients experienced structural and functional deterioration at the follow-up. The study also identified 2 predominant variants and 2 new variants. Homozygotes had an earlier onset of the disease.
{"title":"Un estudio ambispectivo sobre la progresión fenotípica de los pacientes con enfermedad de Stargardt por mutación en el gen ABCA4","authors":"V.A. Martel Ramirez, C.R. Pérez Montaño, A.Y. Hernández Vázquez, S. Rojas Juárez, J.A. Ramírez Estudillo","doi":"10.1016/j.oftal.2025.06.005","DOIUrl":"10.1016/j.oftal.2025.06.005","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to describe the phenotypic progression of patients with Stargardt disease caused by mutations in the <em>ABCA4</em> gene and reports on the mutated allelic variants.</div></div><div><h3>Method</h3><div>We conducted an observational, ambispective, and descriptive study. Patients who had Stargardt disease by the <em>ABCA4</em> gene mutation were included. The study used the genetic report and the baseline examinations appearing on health records. To evaluate the phenotypic variation, a new ophthalmological evaluation was conducted using macular OCT, retinography, autofluorescence, and electroretinogram.</div></div><div><h3>Results</h3><div>The study identified a total of 32 cases with a mean follow-up of 6 years. The mean age of onset was 16 years. The mean initial and final VA were 0.79 and 0.95 logMAR, respectively. The mean initial and final CMT were 142.5 and 135 microns, respectively. The predominant degree of fundus involvement and autofluorescence pattern at the beginning and end was macular atrophy with flecks and the low signal of macular autofluorescence surrounded by a heterogeneous background, respectively. Initial electroretinography showed predominantly preserved function of rods and cones, while in the end most cases presented rod and cone system dysfunction. A total of 9 cases were homozygous, and 31 different mutant allelic variants were identified. The most common variant was p.Trp1618Cys, followed by p.Ala1773Val. Two new allelic variants, p.Leu634Pro, and p.Tyr665Serfs*5, were also discovered.</div></div><div><h3>Conclusions</h3><div>The study found that patients experienced structural and functional deterioration at the follow-up. The study also identified 2 predominant variants and 2 new variants. Homozygotes had an earlier onset of the disease.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 9","pages":"Pages 528-536"},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144912377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.oftal.2025.03.008
S. Menchaca Gutiérrez, L.F. Yañez Ortega, E. Sánchez Hernández
Objective
To determine the correlation of poor visual prognosis biomarkers by Optical Coherence Tomography (OCT) in diabetic macular edema with the level of albuminuria in patients with Chronic Kidney Disease.
Design
This is a retrospective, observational, cross-sectional, and analytical study
Participants
All patients diagnosed with diabetic macular edema who attended the retina department of the Ophthalmology service and met the inclusion criteria between March 2021 and August 2022.
Methods
Data gathering was done through medical record reviews and the patients were divided based on 3 categories of albuminuria. OCT images of the affected eye, which was considered to be the one that was eligible for anti- VEGF treatment, were collected and analyzed, and the corresponding subdivision was made depending on the presence of poor visual prognosis OCT biomarkers.
Results
Chi-square goodness-of-fit tests were performed to analyze whether the proportion of biomarkers in each albuminuria category is due to chance or is related to each A1-A3 albuminuria level. A direct correlation was found between the absence of integrity in the outer retinal layers and the severity of albuminuria.
Conclusions
OCT may serve as a valuable tool for detecting kidney damage by considering the relationship between certain biomarkers and the presence of albuminuria, particularly the disruption of the outer retinal layers, which could serve as an OCT biomarker for advanced kidney disease.
{"title":"Correlación entre biomarcadores de mal pronóstico visual por tomografía de coherencia óptica en edema macular diabético y el nivel de albuminuria en pacientes con enfermedad renal crónica","authors":"S. Menchaca Gutiérrez, L.F. Yañez Ortega, E. Sánchez Hernández","doi":"10.1016/j.oftal.2025.03.008","DOIUrl":"10.1016/j.oftal.2025.03.008","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the correlation of poor visual prognosis biomarkers by Optical Coherence Tomography (OCT) in diabetic macular edema with the level of albuminuria in patients with Chronic Kidney Disease.</div></div><div><h3>Design</h3><div>This is a retrospective, observational, cross-sectional, and analytical study</div></div><div><h3>Participants</h3><div>All patients diagnosed with diabetic macular edema who attended the retina department of the Ophthalmology service and met the inclusion criteria between March 2021 and August 2022.</div></div><div><h3>Methods</h3><div>Data gathering was done through medical record reviews and the patients were divided based on 3 categories of albuminuria. OCT images of the affected eye, which was considered to be the one that was eligible for anti- VEGF treatment, were collected and analyzed, and the corresponding subdivision was made depending on the presence of poor visual prognosis OCT biomarkers.</div></div><div><h3>Results</h3><div>Chi-square goodness-of-fit tests were performed to analyze whether the proportion of biomarkers in each albuminuria category is due to chance or is related to each A1-A3 albuminuria level. A direct correlation was found between the absence of integrity in the outer retinal layers and the severity of albuminuria.</div></div><div><h3>Conclusions</h3><div>OCT may serve as a valuable tool for detecting kidney damage by considering the relationship between certain biomarkers and the presence of albuminuria, particularly the disruption of the outer retinal layers, which could serve as an OCT biomarker for advanced kidney disease.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"100 7","pages":"Pages 392-396"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号